Worth a Shot? Evidence-Based Approach to Prescribing LAI Antipsychotic Medications-View Presentation Slides

View Presentation Slides

Pdf Summary

This 2022 American Psychiatric Association webinar titled "Worth a Shot? Evidence Based Approach to Prescribing LAI Antipsychotic Medications" reviews the use of long-acting injectable (LAI) antipsychotics compared to oral antipsychotics (OAP) in treating schizophrenia, emphasizing evidence-based findings and APA guidelines.

Key points include:

1. <strong>APA Recommendations:</strong> APA suggests LAIs for patients preferring them or with poor/uncertain adherence to oral meds, noting LAIs improve adherence, reduce mortality, hospitalizations, and treatment discontinuations. LAIs also enhance symptom control and reduce conflicts about medication taking.

2. <strong>Medication Adherence Challenges:</strong> Studies reveal poor adherence is common with oral antipsychotics, often underestimated by clinicians and patients. Electronic monitoring shows up to 57% nonadherence, contributing to inadequate therapeutic drug levels in many patients.

3. <strong>Efficacy and Outcomes:</strong> Multiple studies indicate LAIs outperform oral treatments in real-world settings, showing lower rates of treatment failure, rehospitalization, violence, and mortality. For example, paliperidone palmitate LAI demonstrated significantly longer time to treatment failure and fewer hospitalizations compared to oral drugs.

4. <strong>Cost and Healthcare Impact:</strong> LAIs reduce hospitalization rates, inpatient days, emergency visits, and overall medical costs despite higher medication costs, representing cost-effectiveness in schizophrenia management.

5. <strong>Comparisons of First-Generation (FGA) vs. Second-Generation (SGA) LAIs:</strong> SGA-LAIs are associated with better adherence and less polypharmacy than FGAs; FGA-LAIs showed no significant adherence improvement and more antipsychotic polypharmacy relative to oral treatments.

6. <strong>Limitations:</strong> Data lack in-depth subgroup analyses (race, ethnicity, setting), and randomized controlled trials (RCTs) show mixed findings, though observational studies generally support LAIs.

In summary, LAIs offer meaningful advantages over oral antipsychotics in treatment adherence, clinical outcomes, and cost-effectiveness for schizophrenia, especially with second-generation formulations. Early initiation of LAIs may further reduce hospitalizations and healthcare costs. The presentation encourages clinicians to consider patient preference and adherence history when prescribing LAIs.

Keywords

long-acting injectable antipsychotics

oral antipsychotics

schizophrenia treatment

medication adherence

American Psychiatric Association guidelines

first-generation vs second-generation LAIs

treatment outcomes

hospitalization reduction

cost-effectiveness

paliperidone palmitate